Pliant Therapeutics Inc Cash Flow-to-Debt Ratio
Pliant Therapeutics Inc cash flow-to-debt ratio. Pliant Therapeutics Inc (PLRX) has a Cash Flow-to-Debt Ratio of -0.30x as of June 2026, meaning its operating cash flow of $-12.80 Million could theoretically repay 0% of its total liabilities ($42.95 Million) in one year. Check earnings quality score of Pliant Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Pliant Therapeutics Inc (2017–2025)
Cash flow-to-debt ratio of Pliant Therapeutics Inc from 2017 to 2025. Historical debt coverage capacity for Pliant Therapeutics Inc across 9 annual periods. Check how aggressively does Pliant Therapeutics Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Pliant Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2017–2025)
Pliant Therapeutics Inc cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Pliant Therapeutics Inc. For the full cash flow conversion analysis, see PLRX operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.92x | $-128.34 Million | $44.02 Million | ▼ -74.1% |
| 2024 | -1.67x | $-155.50 Million | $92.87 Million | ▲ +44.5% |
| 2023 | -3.02x | $-116.36 Million | $38.58 Million | ▼ -18.8% |
| 2022 | -2.54x | $-94.63 Million | $37.27 Million | ▲ +25.4% |
| 2021 | -3.41x | $-75.44 Million | $22.16 Million | ▼ -13.9% |
| 2020 | -2.99x | $-37.27 Million | $12.46 Million | ▼ -12893.0% |
| 2019 | -0.02x | $-2.75 Million | $119.50 Million | ▲ +94.5% |
| 2018 | -0.42x | $-28.33 Million | $67.41 Million | ▲ +92.1% |
| 2017 | -5.31x | $-16.92 Million | $3.19 Million | — |